T1	intervention 44 73	capecitabine plus enzastaurin
T2	control 81 106	capecitabine plus placebo
T3	eligibility 110 206	patients with metastatic or recurrent breast cancer after prior anthracycline and taxane therapy
T4	outcome-Measure 863 894	progression-free survival (PFS)
T5	total-participants 960 963	109
T6	total-participants 999 1001	85
T7	intervention-participants 1042 1044	42
T8	control-participants 1049 1051	43
T9	outcome 1171 1181	Median PFS
T10	iv-cont-median 1195 1198	2.8
T11	cv-cont-median 1258 1261	4.3
T14	outcome 1365 1388	Median overall survival
T15	iv-cont-median 1480 1483	9.9
T16	cv-cont-median 1505 1509	14.9
T17	outcome 1541 1565	Grade 3/4 adverse events
T18	iv-bin-percent 1621 1626	42.9%
T19	cv-bin-percent 1630 1635	32.6%
